Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patidegib gel 2% for prevention of facial basal cell carcinomas in adults with Gorlin syndrome
NL-OMON60652Phase 3Completed
- Sponsor
- Sol-Gel Technologies
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Basal cell nevus syndrome (BCNS) and basal cell carcinoma (BCC) comparing Patidegib Gel 2% with Vehicle (2 arms). Primary endpoint: Number of new basal cell carcinomas at Month 12. Started May 2024; status: completed.
02
Drugs
patidegib
03
Conditions
Basal cell nevus syndrome (BCNS)basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NL-OMON60652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60652.